Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.

Studied

A prespecified pooled analysis combined individual patient data from two randomized placebo-controlled semaglutide trials in obesity-related HFpEF.

Who / model

Participants had obesity-related heart failure with preserved ejection fraction and symptomatic physical limitations; one trial included diabetes and the other excluded it.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Semaglutide improved heart-failure symptoms and physical limitations and reduced body weight versus placebo, with effects largely consistent across examined subgroups.

Limits

This was a pooled analysis of two trials with defined obesity-related HFpEF eligibility, which limits interpretation outside that population.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary